Allergan announced over the weekend that it agreed to pay $560m plus undisclosed milestone fees for novel depression drug developer Naurex, but the company remained quiet about the rumored sale of its generics business to Teva Pharmaceutical Industries for several billion dollars.
A spokesman said on 26 July that Allergan had no comment about speculation that the company would accept a $45bn bid for its generic medicines unit, which generated $6.7bn in sales in 2014